Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Stratified and MRD-Driven Maintenance in MM Post-ASCT
NCT06697483Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Minimal Residual Disease status at 12 months. Started Dec 2024; status: recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06697483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06697483.